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1. Aims and objectives 
 
To evaluate whether, using the current antibiotic regimens, plasma concentrations of 
cefazolin remain above four times the minimum inhibitory concentration (MIC) for 
common pathogens for the intraoperative period in children undergoing elective 
cardiac surgery involving cardiopulmonary bypass (CPB). 
 
Our secondary objectives are: 
• To determine if the second dose should be given earlier than the current 
regimen of giving a second dose four to six hours after initial dose,  
• To determine if the bypass pump should be routinely primed with a dose 
of cefazolin, as is the practice of some anaesthesiologists. 
• To determine if a second dose is required during prolonged CPB 
 
2. Background to study  
 
Our current antibiotic prophylaxis practice at Red Cross War Memorial Children’s 
Hospital (RCWMCH) is to administer a dose of cefazolin 50 mg / kg of body weight 
at the time of induction of anaesthesia.  This is followed by a second dose four to six 
hours later.  It is also acceptable practice to add an additional dose (also 50 mg / kg) 
to the priming volume of the bypass pump, although not all cardiac 
anaesthesiologists routinely do this.  Children weighing between 20 and 25 kg will 
receive a dose of 1000 mg.  A further dose is given 6 hours later in the intensive care 
unit (ICU). 
 
Our antibiotic prophylaxis for cardiac surgery at RCWMCH was previously 
cloxacillin and gentamicin, but it changed to cefazolin in 2009 in order to standardise 
the surgical prophylaxis across all disciplines.  This was as per the microbiologists’ 
advice and is in keeping with international practice (see 3.2 below).  There was a 
cluster of sternal wound infection (SWI) at our institution in 2010, which led to a 
multidisciplinary investigation into the contributing factors.  One of the factors was 
the concern around the choice of cefazolin as the sole antibiotic prophylactic agent 
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preoperative preparation of the child, skin hygiene, ward protocols and theatre 
practice.  No single cause was identified, but increased vigilance of the above factors 
has led to reduction in the incidence of SWI.  The questions regarding the dosing 
regimen of cefazolin in children requiring cardiac surgery on CPB remain 
unanswered.  The bacterial resistance patterns in our paediatric population have not 
changed recently, although some institutions are reporting an increase in methicillin-
resistant Staphylococcus aureus (MRSA).   
 
It is difficult to get an accurate incidence of SWI following elective cardiac surgery 
at RCWMCH.  A formal audit of the current incidence has not yet been performed.  
Anecdotal evidence suggests that the incidence is within international standards of 
less than 5 %.  There has not been an overall noticeable rise in the rate of surgical 
site infections at our institution. 
 
The microbiology department at RCWMCH does not routinely collect data in this 
group of children.  As their data is sorted according to the ward to which the patient 
is admitted, they are not able to isolate the data from this specific subset of children.   
 
The morbidity and mortality from surgical site infections is significant and all 
measures should be taken to ensure the reduction in the incidence of postoperative 
sternal wound sepsis.  
 
During CPB, the plasma levels of all drugs may be altered, due to, among other 
factors, the greater volume of distribution. 1   Cefazolin is a time-dependent 
antibacterial agent so its bactericidal action depends on the duration of time that the 
plasma concentrations are above the MIC for the causative bacteria.2  Some sources 
suggest that the concentrations should remain above MIC for only 40 to 50 % of the 
dosing interval in treatment regimens.3  As intraoperative contamination can occur at 
any point during surgery, it is suggested that the dosing regimen for prophylaxis 
should aim for plasma levels over MIC for 100 % of the surgical duration as well as 
for at least a few hours after closure of the skin incision.4 Inadequate plasma 
concentrations of cefazolin in the perioperative period may contribute to the 












Our institution does not measure the MIC of sensitive microorganisms for cefazolin, 
as this drug is only currently recommended for surgical prophylaxis.  Alternative 
antimicrobial agents are offered for treatment of postoperative wound infections, 
based on empirical data and then changed as necessary according to culture results.   
This study may reveal that our current protocol produces ineffective plasma 
concentrations of cefazolin due to the effects of CPB.  The findings from this 
research project could potentially lead to a more effective dosing regimen while on 
CPB.  
3. Literature review
3.1 Sternal wound infections in paediatric cardiac surgery 
The incidence of SWI following cardiac surgery in the paediatric population is 
reported to be between 0.2 % and 4.8 %.5 This is similar to that in the adult 
population. The limited published data in this population group is difficult to 
compare as the reported depth of SWI varies from superficial incisional to deep 
incisional to organ space infections.   
Guidelines exist for the prevention of SWI for adult patients. 6 There are no 
equivalent international guidelines for paediatric patients, and various paediatric 
cardiac surgery centres have been using either adapted adult guidelines, or locally 
produced protocols. 
The risk factors for SWI in children vary greatly from those in adults.  In the adult 
population, diabetes, obesity and chronic obstructive pulmonary disease are some of 
the major risk factors for SWI.7  Various risk factors have been shown to increase the 
chance of SWI in children.  Edwards et al. showed that a pump bypass time of 
greater than one hour, excessive postoperative bleeding, a low cardiac output state 
for 24 to 72 hours postoperatively and re-exploration for the control of bleeding were 
all risk factors for the development of SWI.8  They also proposed that inadequate 
antibiotic prophylaxis was an additional risk factor.  Mehta et al. assessed risk 











They found an increased incidence of SWI in children of younger age, higher 
American Society of Anesthesiologists (ASA) score, longer preoperative stay, longer 
period of ventilation and inotropic support, longer stay on the ICU longer hospital 
stay and increased preoperative leucocyte band cell counts.  Children with associated 
pre-existing conditions were also at an increased risk of SWI.  Ben-Ami et al. 
showed three variables as independent risk factors for SWI: young age, cyanotic 
heart disease and prolonged central venous catheter dwell time.10 
3.2 Prophylactic antibiotics in paediatric cardiac surgery 
A review of perioperative antibiotic prophylaxis in paediatric cardiac surgery was 
published in 2007.11 The choice of antibiotic, timing of dose and duration of therapy 
of prophylactic antimicrobials in paediatric cardiac surgery has been well debated. A 
meta-analysis of four placebo-controlled trials established antibiotic prophylaxis as 
the standard of practice in cardiac surgery, and concluded that further placebo-
controlled trials would be unethical.12 They also showed a reduction of SWI in 
patients treated with a cephalosporin, with an odds ratio of 0.51. Numerous 
comparisons between the first and second-generation cephalosporins have shown no 
statistical difference between the two groups.  
Vancomycin appears to be no more effective than the cephalosporins in 
cardiothoracic surgical centres that have a lower incidence of MRSA infections.11
Due to its side-effect profile, it is suggested that vancomycin be restricted to use in 
children with penicillin or cephalosporin allergies and in centres with a high 
incidence of MRSA.
There is insufficient evidence for the routine use of gentamicin as prophylaxis for 
cardiac surgery.11 
The duration of the prophylaxis is debatable.  General consensus is that antibiotic 
prophylaxis should not be continued for longer than 48 hours following major 
surgery.  The Society of Thoracic Surgeons Workforce on Evidence Based Surgery 











there is inconclusive data.13 An study involving 838 adult patients undergoing 
cardiac surgery showed a higher incidence of SWI in the group which only received 
a single dose at induction compared to a group which received multiple doses over 
the 24-hour postoperative period (8.3 % vs 3.6 %, p = 0.004).14 
A retrospective review of three antibiotic prophylaxis regimens in paediatric cardiac 
surgical patients analysed three protocols used over a six-year period.15  They 
showed a reduced incidence of SWI’s in the group that received on-going 
prophylactic antibiotics until the chest tubes were removed.  All their regimens used 
a dose of cefazolin of 50 mg / kg.   
3.3 Cefazolin 
3.3.1 Microbial action 
Cefazolin is a first generation cephalosporin, which was first evaluated for clinical 
use in the early 1970’s.16 It is a semi-synthetic derivative of cephalosporin C, with 
bactericidal activity against most gram-positive cocci (except enterococci and 
MRSA) and at higher concentrations against Escherichia coli, Klebsiella pneumonia, 
Proteus mirabilis, Salmonella spp., and Shigella spp. 
The breakpoint is the level of MIC at which a bacterium is deemed either susceptible 
or resistant to an antibiotic being used. If either the MIC of a particular strain or the 
MIC90 of a group strain is found to be at or below this breakpoint, the organism(s) 
can be considered ‘susceptible’. If it is above the breakpoint, it is deemed 
‘resistant’.3 The most recent data on the pharmacokinetic and pharmacodynamic 
breakpoints of cefazolin for Staphylococcus spp. and Enterobacteriaceae spp. was 
published in January 2012.17 The MIC90 is the MIC below which 90 % of a group of 
organisms will show inhibited growth. The MIC90 for sensitive Staphylococcus spp. 
is 8 mcg / mL, for intermediately-sensitive Staphylococcus spp. it is 16 mcg / mL 
and for resistant Staphylococcus spp. 32 mcg / mL. The MIC90 for sensitive 
Enterobacteriaceae spp. is 2 mcg / mL for intermediately-sensitive 
Enterobacteriaceae spp. 8 mcg / mL and for resistant Enterobacteriaceae spp.












Cefazolin remains unchanged in the body, and about 80 – 100 % is excreted 
unchanged in the urine within 24 hours.18 The serum half-life is 1.8 hours.  It is 85 % 
protein bound.  It is eliminated by renal excretion through passive filtration and 
active secretion. 
3.4 Effects of CPB on cefazolin plasma concentrations 
Adults undergoing elective cardiac surgery routinely receive 1 - 2 g of cefazolin 
intravenously 30 – 60 minutes prior to surgery.19 There have been a number of trials 
in adults investigating the effects of CPB on cefazolin plasma concentrations.  
Fellinger et al. looked at the serum cefazolin levels in 10 adults undergoing elective 
and urgent coronary artery bypass grafting. These patients received a dose of 
cefazolin at induction of anaesthesia (1 g) and a further dose immediately after onset 
of CPB. They found that the levels consistently remained above MIC90 for 
Staphylococcus aureus and Staphylococcus epidermidis, but fell below the MIC90 for 
Enterobacter spp., Serratia spp., Escherichia coli and Proteus mirabilis.20
A larger study divided 137 patients into 3 groups.21 Group 1 received 1 g of 
cefazolin at the start of surgery and a second dose at the end of CPB. Group 2 
received 2 g of cefazolin at the start of surgery and a continuous infusion of cefazolin 
at 20 mg per minute throughout surgery. Group 3 received 3 g of cefazolin at the 
start of surgery, followed by a continuous infusion of 15 mg per minute throughout 
surgery. Group 3 had statistically higher cefazolin concentrations at all time points 
when compared with Group 1 (p < 0.02) and most time points when compared with 
Group 2 (p > 0.04). This study suggested a larger pre-operative bolus, followed by a 
continuous infusion will result in higher serum and tissue concentrations. No related 
toxicity was reported.
Another study comparing an initial cefazolin bolus of 2 g followed by either further 
intermittent doses at 3, 9 and 15 hours, or a continuous infusion for 18 hours found 
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continuous infusion regimen.22  They had 10 subjects in each group and measured 
blood and atrial myocardial tissue levels of cefazolin.  They found that a larger initial 
dose, followed by the continuous infusion led to superior serum and tissue 
concentrations, at all intraoperative intervals, with no related toxicity or adverse 
events. 
 
The effects of profound hypothermic arrest have also been studied.23  Four groups of 
10 patients receiving cefazolin prophylaxis were studied.  Group A underwent 
vascular surgery without CPB.  Group B had cardiac surgery with CPB time of less 
than 120 minutes.  Group C had cardiac surgery with a CPB time of greater than 
120 minutes and Group D had cardiac surgery with profound hypothermic 
circulatory arrest.  They all received cefazolin at induction and a second dose before 
wound closure.  Their plasma concentrations of cefazolin were measured at set 
intervals during surgery.  Patients in Group A had levels above 16 mcg / mL 
throughout surgery.  Group B had levels above the MIC for sensitive Staphylococcus 
aureus (8 mcg / mL), but below 16 mcg / mL for 30 % of the time.  Group C patients 
had levels below 8 mcg / mL in 50 % of patients.  Group D showed better levels, and 
only one patient had levels below inhibitory concentrations.  They concluded that 
their regimen was generally suboptimal and recommended further studies to 
investigate a more suitable protocol, but patients undergoing profound hypothermic 
circulatory arrest are better protected. 
 
O’Rullian et al. investigated whether the use of ultrafiltration at the end of CPB had 
an effect on cefazolin levels.24  This was a small study, which included five adult 
patients who received ultrafiltration after CPB and six patients who had CPB without 
ultrafiltration.  They analysed three blood samples from each case.  They showed no 
significant variation between the plasma levels in the two groups, concluding that 
ultrafiltration does not affect the serum levels of cefazolin.  The limitations of this 
trial were due to its small sample size and only three sampling points in each case.   
 
A study investigating cefazolin levels in children undergoing CPB was published in 
2003.25  Haessler et al. performed a prospective study of 19 infants weighing less 
than 10 kg, undergoing cardiac surgery requiring CPB.  These children received 











further doses of cefazolin 35 mg / kg every 8 hours and gentamicin 2 mg / kg every 
12 hours for a total of 48 hours.  They showed adequate levels of cefazolin 
throughout the perioperative period on this regimen, although the peak gentamicin 
levels were high intraoperatively.  They commented that their study had limited 
postoperative samples. 
4. Scientific design
The study will be a non-interventional observational prospective study of 
15 to 20 children undergoing elective cardiac surgery requiring CPB at Red Cross 
War Memorial Children’s Hospital (RCWMCH) in Cape Town. 
The study will be conducted in accordance with the South African Good Clinical 
Practice Guidelines and the Declaration of Helsinki.
Patients will all receive standard perioperative anaesthetic and surgical care, 
according to the current practice at RCWMCH.
An initial dose of cefazolin 50 mg / kg of body weight will be administered as an 
intravenous infusion over one minute, following induction of anaesthesia, via a 
peripheral intravenous line. A second dose (50 mg / kg) can be given four to six
hours after the first dose. This may occur intraoperatively during CPB or 
postoperatively on the ICU. Two of the cardiac anaesthesiologists routinely add a 
further dose of cefazolin (50 mg / kg) to the CPB circuit prior to going on bypass.  
The administration of the second dose will be documented and these children will be 
analysed in a subset group. This is the current accepted antibiotic prophylaxis
regimen at our institution. There will be no change to the current standard of care.  
The children will not be randomised to either group. 
To assay plasma concentrations of cefazolin, blood samples will be drawn from the 
intra-arterial catheter that is placed routinely in either the femoral or radial arteries 
after induction of anaesthesia.  Most similar studies have used arterial samples.25,26,27 











administration of the dose.  Each sample will not exceed 0.5 mL in volume.  All 
children undergoing cardiac surgery will have an arterial catheter placed, so this 
study will not require any additional invasive lines.  The total volume of blood drawn 
from each subject will not exceed 8 mL (16 samples).  Most children will have 
13 to 16 samples. 
A baseline sample will be taken prior to the first dose of cefazolin. The second dose 
will be taken three minutes after the completion of the initial dose infusion. This will 
determine the peak plasma concentration after the intravenous bolus of cefazolin.  
The third sample will be taken at the time of sternal incision. The fourth sample will 
be taken at the immediately prior to commencement of CPB (at the time of 
cannulation of the aorta). The fifth sample will be taken once full flow CPB is 
established. Further samples will be taken every 30 to 60 minutes while on CPB, 
and immediately before the end of CPB. The next sample will be once off CPB, at 
skin closure, and then immediately prior to the next dose of cefazolin (trough level), 
four to six hours after the initial dose. 
In order to perform future pharmacokinetic studies of the effects of CPB on cefazolin 
plasma concentrations, a control population is required. Following the second dose 
of cefazolin in the ICU, a peak level will be measured, and then two to three further 
samples at one to four hours post dose. This is to reduce the variables, which 
contribute to pharmacokinetic differences between individuals and accurately 
determine the actual effects of the CPB. 
The samples will be stored on ice for a maximum of six hours and then centrifuged 
by the principal investigator.  The plasma will be stored at minus 70 degrees 
centigrade.  These samples will initially be stored at the laboratory at RCWMCH, 
and then moved to the Department of Pharmacology at the University of Cape Town, 
where they will be analysed.  The storage facilities and transport arrangements have 
been assessed by the Department of Pharmacology as being both valid and adequate 











Figure 1: Time course of antibiotic administration and blood samples
5. Subject selection
The study will include up to 20 consecutive children with a body weight of less than 
25 kg, undergoing elective cardiac surgery requiring cardiopulmonary bypass.
Valid informed consent will be obtained from the child’s parent or legal guardian, 
once eligibility for the study has been confirmed. The principal investigator will 
personally obtain informed, written consent from the child’s legal guardian or parent.  
This interview will take place on the day prior to the elective surgery. Adequate time 
will be spent with the parent, allowing full explanation of the planned procedures and 
time for questions to be answered adequately. An information leaflet will be 
provided in English, Afrikaans or isiXhosa, and the consent form will also be 
available in these languages. The parent or legal guardian will be informed that their 
consent can be withdrawn at any stage and that this will not compromise the care of 
their child in any way. An independent witness will be present during the consent 
interview to ensure the absence of undue influence and coercion.
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The inclusion criteria are as follows: 
1) Body weight of less than 25 kilograms
2) Elective cardiac surgery requiring CPB
3) Valid informed consent from the parent or legal guardian to participate in the
study and to store specimens for immediate and future analysis
The exclusion criteria are as follows: 
1) Expected CPB time of less than 30 minutes
2) History of allergy to penicillin or cephalosporins
3) Pre-existing renal or hepatic dysfunction
4) Exposure to any antimicrobial agent within the previous week 
5) History of a recent infection
6. Measurement and statistical analysis
The blood samples will be sent to the University of Cape Town’s Pharmacology 
Department, where they will be analysed. This department is currently developing 
an appropriate assay to measure the cefazolin plasma levels. The reference standards 
have been purchased, and the assay method will be validated according to
international standards. The measurement will be by liquid chromatography and 
mass spectrometry.
This is a non-interventional, observational study and not a comparison between 
treatment modalities so a power calculation is not necessary.  
Any documented SWI during the 14 postoperative days will be recorded.  The 
patient’s clinical record will be used to assess the nature of the wound infection, the 
results of any microbiological tests performed and the antibiotic therapy required.  
This is purely for descriptive purposes as the sample size is inadequate to make any 
clinically or statistically significant conclusions. 
The plasma concentrations profiles will be interpreted with non-linear mixed-effects 
modelling, using the software NONMEM®.  This technique is largely used in the 
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semi-mechanistic explanation for the changes in drug concentration.  Moreover, it is 
able to identify and quantify the separate sources of variability in the data, such as 
measurement error and the physiologically driven differences in parameter values 
between subjects.  Body size, renal function, age, gender and other relevant co-
variates will be tested as predictors for the between subject variability and integrated 
in the model if found significant.  The pharmacokinetic model will then be used for 
simulation of confidence intervals and will provide a platform to investigate different 
dosing scenarios and optimize the drug administration.  
 
Statistical analysis will be done using Stata® data analysis and statistical software.  A 
histogram will be used for each variable to test for normality.  A p-value of less than 
0.05 will be considered to be statistically significant.   
 
7. Additional data collection 
 
The following data will also be collected from each study subject: 
1. Age, gender, height and weight 
2. Type of surgery performed and details of cardiopulmonary bypass 
(duration of CPB and aortic cross-clamp) 
3. Concurrent medication 
4. Co-morbidities 
5. All drugs administered during surgery 
6. All intravenous fluids and blood products administered during surgery 
7. Serum haematocrit values throughout surgery (routinely tested on arterial 
blood gas analysis) 
8. Anatomical site of intravenous and intra-arterial catheters 
9. Type and volume of cardioplegia used 
10. Preoperative renal function and estimated glomerular filtration rate (using 
the Schwartz formula). 
11.  Any evidence of SWI in the first 14 days following surgery (documented 
wound infection in patient records by the cardiothoracic surgical team, 
pus swab and blood culture results and the need for additional 
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8. Confidentiality 
 
The consent form will bear the child’s name and date of birth, but this information 
will be kept in a safe, locked location.  Further identification of the samples will be 
by means of a unique number, which will correspond to each subject.   
 
9. Conflicts of interest 
 











	   19	  
References
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
1 Buylaert WA, Herregods LL, Mortier EP, et al: Cardiopulmonary bypass and the 
pharmacokinetics of drugs. Clin Pharmacokinet 17(1):10-26, 1989 
2 Craig W: Pharmacodynamics of antimicrobial agents as a basis for determining 
2 Craig W: Pharmacodynamics of antimicrobial agents as a basis for determining 
dosage regimens. Eur J Clin Microbiol Infect Dis 12(Suppl 1):S6-8, 1993 
3 Jacobs MR: Optimisation of antimicrobial therapy using pharmacokinetic and 
pharmacodynamic parameters. Clin Microbiol Infect 7:589-596, 2001 
4  Moine P, Fish DN: Pharmacodynamic modelling of intravenous antibiotic 
prophylaxis in elective colorectal surgery. Int J Antimicrob Agents 41:167-173, 2013 
5 Woodward CS, Son M, Calhoon J, et al: Sternal wound infections in pediatric 
congenital cardiac surgery: A survey of incidence and preventative practice. Ann 
Thorac Surg 91:799-804, 2011 
6  Kohut K: Guide for the prevention of mediastinitis surgical site infections 
following cardiac surgery.  Association for Professionals in Infection Control and 
Epidemiology (www.apic.org), 2008 
7 Filsoufi F, Castillo JG, Rahmanian PB, et al: Epidemiology of deep sternal wound 
infection in cardiac surgery. J Cardiothor Vasc Anesth 23(4):488-494,2009 
8	  Edwards MS, Baker CJ: Median sternotomy wound infections in children. Pediatr 
Infect Dis. J 2(2):105-109, 1983	  
9	  Mehta PA, Cunningham CK, Colella CB, et al: Risk factors for sternal wound and 
other infections in pediatric cardiac surgery patients.  Pediatr Infect Dis J 
19(10):1000-1004, 2000	  
10 Ben-Ami E, Levy I, Katz J, et al: Risk factors for sternal wound infection in 
children undergoing cardiac surgery: a case-control study. J Hosp Infect 70:335-340, 
2008 
11 Alphonso N, Anagnostopoulos PV, Scarpace S, et al: Perioperative antibiotic 
prophylaxis in paediatric cardiac surgery. Cardiol Young 17:12-25, 2007 
12 Kreter B, Woods M: Antibiotic prophylaxis for cardiothoracic operations.  Meta-











	   20	  
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
13 Edwards FH, Engelman RM, Houck P, et al: The Society of Thoracic Surgeons 
Practice Guideline series: Antibiotic prophylaxis in cardiac surgery, Part I: Duration. 
Ann Thorac Surg 81:397-404, 2006 
14 Tamayo E, Gualis J, Florez S, et al: Comparative study of single-dose and 24-hour 
multiple-dose antibiotic prophylaxis for cardiac surgery. J Thorac Cardiovasc Surg 
136:1522-1527, 2008 
15 Maher KO, van der Elzen K, Bove EL, et al: A retrospective review of three 
antibiotic prophylaxis regimens for pediatric cardiac surgical patients. Ann Thorac 
Surg 74:1195-1200, 2002 
16  Reller LB, Karney WW, Beaty HN, et al: Evaluation of cefazolin, a new 
cephalosporin antibiotic. Antimicrob Agents Chemother 3(4): 488-497, 1973 
17  Performance Standard for Antimicrobial Susceptibility Testing. CLSI. 22nd 
Informational Supplement. Document M100-S22: 32(3), 2012 
18 Quintiliani R, Nightingale CH: Cefazolin. Ann Intern Med 89(1):650-656, 1978 
19 Engelman R, Shahian D, Shemin R, et al: The Society of Thoracic Surgeons 
Practice Guideline series: Antibiotic prophylaxis in cardiac surgery, Part II: 
Antibiotic choice. Ann Thorac Surg 83:1569-1576, 2007 
20 Fellinger EK, Leavitt BJ, Hebert JC: Serum levels of prophylactic cefazolin during 
cardiopulmonary bypass surgery. Ann Thorac Surg 74:1187-1190, 2002 
21 Waltrip T, Lewis R, Young V, et al: A pilot study to determine the feasibility of 
continuous cefazolin infusion. Surg Infect 3(1): 5-9, 2002 
22  Adembri C, R stori R, Chelazzi C, et al: Cefazolin bolus and continuous 
administration for elective cardiac surgery: Improved pharmacokinetic and 
pharmacodynamic parameters. J Thorac Cardiovasc Surg 140(2): 471-475, 2010 
23  Caffarelli AD, Holden JP, Baron EJ, et al: Plasma cefazolin levels during 
cardiovascular surgery: Effects of cardiopulmonary bypass and profound 
hypothermic circulatory arrest. J Thorac Cardiovasc Surg 131(6):1338-1343, 2006 
24 O’Rullian JJ, Wise RK, McCoach RM, et al: The effects of haemofiltration on 
cefazolin levels during cardiopulmonary bypass. Perfusion 13:176-180, 1998 
25 Haessler D, Reverdy ME, Neidecker J, et al: Antibiotic prophylaxis with cefazolin 
and gentamicin in cardiac surgery for children less than ten kilograms. J 










	   21	  
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
26 Fellinger EK, Leavitt BJ, Hebert JC: Serum levels of prophylactic cefazolin during 
cardiopulmonary bypass surgery. Ann Thorac Surg 74:1187-1190, 2002 
27 Lehot JJ, Reverdy ME, Etienne J, et al: Cefazolin and netilmicin serum levels 
during and after cardiac surgery with cardiopulmonary bypass. J Cardiothorac 






















1. Objectives of literature review
The main objectives of this literature review are to critically review the current 
published literature about cefazolin pharmacokinetics, including the influence of 
cardiopulmonary bypass (CPB) on cefazolin plasma concentrations, and to evaluate 
the drug’s usage and dosing regimens as a prophylactic antibiotic in paediatric 
cardiac surgery.  Published paediatric data is limited in this field and thus 
consideration and extrapolation of data from the adult population data will be 
required.   
2. Literature search strategy
A PubMed literature search was performed, using the free text and MeSH thesaurus 
terms ‘cefazolin’ or ‘cephalosporin’ with ‘cardiac surgery’, ‘cardiopulmonary 
bypass’, or pharmacokinetics’; as well as ‘cardiac surgery’ with ‘sternal wound 
infections’, ‘antibiotic prophylaxis’. Both adult and paediatric data was reviewed, 
with an emphasis placed on paediatric literature. Literature published between 
January 1970 and December 2012 was included. Literature was excluded from the 
review if it had not been originally published in the English language.  
3. Review and critical appraisal of the literature
3.1. Pharmacological properties of cefazolin 
Cefazolin is a semi-synthetic first generation cephalosporin that was developed in the 
1970’s.  It has enjoyed widespread use, initially as a therapeutic antimicrobial agent 
and more recently as the recommended prophylactic antibiotic for many surgical 
procedures.  
Cefazolin can be administered either by the intramuscular or the intravenous route.  










	   24 
passive filtration and active secretion.  The plasma half-life is 1.8 hours and it is 
85 % protein-bound.1 
 
The adverse effects of cefazolin are limited to allergic phenomena and mild 
symptoms of nausea and burning on injection.  In experimental animal studies, 
cephalosporins have been shown to cause damage to proximal renal tubular cells.2  
The only published human cases of possible cefazolin toxicity suggested that high 
cerebrospinal fluid concentrations (CSF) of cefazolin (34 – 106 mcg / mL) were 
associated with seizures in three adult patients.3 No reference range exists for CSF 
cefazolin concentrations, and the correlated serum levels were 360 – 1000 mcg / mL. 
 
Gram-positive cocci (with the exception of enterococci and methicillin-resistant 
staphylococci) are generally susceptible to cefazolin.  Of the gram-negative bacilli, 
only Escherichia coli, Klebsiella pneumoniae, Proteus mirabilis, Salmonella spp. 
and Shigella spp. are modestly sensitive to cefazolin.1 The remaining gram-negative 
organisms are generally resistant. 
 
The minimum inhibitory concentration (MIC) of an antimicrobial is defined as the 
lowest concentration that will inhibit visible growth of a microorganism after 
overnight incubation in a culture medium.  By contrast, the minimum bactericidal 
concentration (MBC) is the lowest concentration of antimicrobial that will prevent 
growth of the organism, after subculture onto antimicrobial free media.4 
 
Reller et al. investigated the clinical efficacy of cefazolin as a therapeutic antibiotic, 
and measured the MIC and MBC for common significant pathogens.5 In this study, 
the MIC of cefazolin for 30 isolates of Staphylococcus aureus (104 organisms / mL) 
(both penicillin-sensitive and penicillin-resistant) was found to be less than 
1 mcg / mL.  Higher inocula of organisms (106 organisms / mL) showed a higher 
MBC of 25 mcg / mL.  The gram-negative pathogens also showed a striking increase 
of the MBC with increasing size of inoculum.  However, these higher inocula are not 












As with the other cephalosporins, the action of cefazolin is by time-dependent 
killing.6 This implies that the inhibitory effect of the antibiotic is dependent on the 
time that the plasma concentration remains above the MIC during the dosing 
interval.  The interstitial fluid concentration is in rapid equilibrium with the serum 
concentration and the bacteria are exposed to external cellular membranes that are in 
contact with the interstitial fluid.  Serum concentrations have, therefore, been 
correlated to in vivo bactericidal action.  The extracellular tissue fluid protein content 
is about one-third of that of the serum.  While the free fraction of cefazolin will be in 
equilibrium between these fluid compartments, the total concentration of a highly 
protein-bound drug will be lower in the tissue fluid.7  
The required time above MIC varies according to pathogen, infection site and drug.  
It is generally accepted that the serum levels should be above MIC for 40 to 50 % of 
the dosing interval when used for therapeutic goals.8 In a study characterising the 
relationship between gentamicin levels during surgery and postoperative wound 
infections in colorectal surgery, the gentamicin plasma concentration at time of skin 
closure was one of the strongest independent risk factors for infection. 9 As 
intraoperative contamination can occur at any point during surgery, it is suggested 
that the dosing regimen should aim for plasma levels over MIC for 100 % of the 
surgical duration as well as for at least a few hours after closure of the skin 
incision.10
Some data suggests that in order to ensure maximal time-dependent killing and 
prevent the development of resistance, a serum concentration at least four times the 
MIC is targeted.7 These studies were conducted both in vitro and in vivo; however, 
the goal was for eradication of an existing micro-organism, not specifically for 
antibiotic prophylaxis.
The breakpoint is the level of MIC at which a bacterium is deemed either susceptible 
or resistant to an antibiotic being used.  The most recent data on the pharmacokinetic 
and pharmacodynamic breakpoints of cefazolin for Staphylococcus spp. and 
Enterobacteriaceae spp. was published in 2012.11 If either the MIC of a particular 
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organism(s) can be considered ‘susceptible’.  If it is above the breakpoint, it is 
deemed ‘resistant’.8 The MIC90 is the MIC below which 90 % of a group of 
organisms will show inhibited growth.  The MIC90 for sensitive Staphylococcus spp. 
is 8 mcg / mL, for intermediately sensitive Staphylococcus spp. it is 16 mcg / mL and 
for resistant Staphylococcus spp. 32 mcg / mL.  The MIC90 for sensitive 
Enterobacteriaceae spp. is 2 mcg / mL for intermediately-sensitive 
Enterobacteriaceae spp. 8 mcg / mL and for resistant Enterobacteriaceae spp. 
16 mcg / mL.   
 
3.2. Effect of cardiopulmonary bypass on cefazolin plasma concentrations 
 
CPB can affect the pharmacokinetics and pharmacodynamics of drugs for a variety 
of reasons.  An increased volume of distribution (with resultant haemodilution), 
altered protein binding, decreased elimination, reduced organ perfusion and 
hypothermia are the main factors.12   
 
Miller et al. considered the effect of CPB on cefazolin pharmacokinetics.13 This 
study had a small sample size of eight adult patients.  They found there was an initial 
decrease in the serum concentrations after initiation of CPB, due mainly to 
haemodilution, followed by a plateau or gradual rise in the levels, due to 
redistribution of the drug.  When comparing the differences in renal clearance 
measured during the pre-bypass, bypass and post-bypass intervals, no significant 
difference was found.  This was a very small study, so statistical significance would 
not have been achieved.   
 
There is limited published data on the alterations to the pharmacokinetic properties 
of drugs in the paediatric population.  The volume of distribution (Vd) of a drug is 
determined by the extent to which the drug penetrates the extravascular 
compartment.  In neonates, the total body weight consists of 80 % water, which then 
decreases over the following four months of life to around 60 %, similar to that of an 
adult.  Hydrophilic drugs such as cefazolin have an increased apparent Vd in this age 











free, unbound form.  The protein-binding capacity of a neonate is also immature, and 
with lower circulating levels of albumin and other plasma proteins an increased free 
fraction of the drug can be anticipated.14  
As cefazolin is excreted unchanged in the urine, the clearance of the drug is 
dependent on the glomerular filtration rate (GFR). The GFR is reduced in neonates, 
reaching and exceeding adult levels in the first few years of life. By six to eight 
years of age, a child’s GFR matches an adult’s GFR. This variation in GFR would 
lead to increased plasma levels of cefazolin in the neonatal population, but reduced 
levels between the ages of two to six years.14 To date, no pharmacokinetic studies 
have been conducted that look at the renal clearance of cefazolin in the paediatric 
population. A study conducted in adults undergoing cardiothoracic surgery (of 
which only 44 % of the cases involved CPB) showed there was a strong negative 
correlation between a preoperative creatinine clearance of less than 50 mL / min and 
time above MIC. A shorter postoperative dosing interval of less than six hours was 
recommended in order to achieve 100 % time above MIC in patients with normal 
renal function.15 This study showed an increase in postoperative surgical site 
infections in the group with a normal preoperative creatinine clearance, but this was 
not statistically significant. 
The effect of hypothermia on serum cefazolin levels was investigated in a 
prospective study by Caffarelli et al.16 This study found that serum cefazolin levels 
were not affected by a CPB duration of less than 120 minutes with mild to moderate 
hypothermia. In cases requiring CPB times of longer than 120 minutes, the plasma 
levels dropped to ineffective therapeutic levels in 50 % of patients. Profound 
hypothermic circulatory arrest appeared to have a slightly protective effect on the 
serum levels. Although these cases also had prolonged CPB times, only 10 % of 
patients had a sub-therapeutic plasma level. This is possibly due to the delayed renal 











3.3. Sternal wound infection in paediatric cardiac surgery 
SWI is a significant cause of morbidity and mortality following elective paediatric 
cardiac surgery. The incidence of SWI following cardiac surgery in the paediatric 
population varies between 0.2 % and 4.8 %.17,18,19 This is similar to that in the adult
population, which is well reported to be between 0.5 % and 7.4 %.20,21,22 The limited 
published data in this population group is difficult to compare as the reported 
severity of SWI varies between studies. SWI following cardiac surgery can be 
classified as either superficial or deep. Superficial infections are limited to the skin 
(superficial incisional) or to the soft tissue overlying the sternum (deep incisional), 
while deep infections extend to the sternum and / or mediastinum.  
International guidelines exist for the prevention of SWI in adult cardiac patients.23
As well as antibiotic prophylaxis, these guidelines also address hand hygiene, blood 
glucose control, the avoidance of preoperative shaving of the surgical field, strict 
surgical skin asepsis, surgical techniques and postoperative wound care. Reducing 
the microbial load by preoperative showering is recommended, and nasal 
decolonization in patients with proven nasal carriage of Staphylococcus aureus is 
shown in some papers to be effective in reducing SWI, but the literature is unclear.  
There are no equivalent international guidelines for paediatric patients, and 
paediatric cardiac surgery centres use adapted adult guidelines, or local protocols. 
3.3.1. Risk factors for sternal wound infection
The risk factors for SWI in children vary greatly from those in adults.  In the adult 
population, diabetes, obesity, previous myocardial infarction and chronic obstructive 
pulmonary disease represent some of the major risk factors for SWI.24  Owing to 
differing disease profiles, these risk factors are not generally transferable to the 
paediatric population.   
Various risk factors have been shown to increase the chance of SWI in children.  
Mehta et al. assessed risk factors for SWI in both elective and emergency paediatric 
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following cardiac surgery, with an incidence of SWI of 5 %.  They found an 
increased incidence of SWI in children with younger age (mean 4.7 months), higher 
ASA score, longer preoperative stay, longer period of ventilation and inotropic 
support, longer intensive care unit stay, longer hospital stay and increased leucocyte 
band cell counts preoperatively.  Children with associated pre-existing conditions 
were also found to be at an increased risk of SWI.   
 
Ben-Ami et al. demonstrated three significant independent risk factors for SWI: 
young age (less than nine months of age), cyanotic heart disease and prolonged 
central venous catheter dwell time.26  This was also a retrospective chart review of 
1821 patients, with an incidence of SWI of 2.7 %.  
 
A further retrospective case-control study of 1017 children showed paediatric cardiac 
patients showed weight (less than 4.5 kg), age (less than 2.5 months) and ASA score 
(greater than 3) to be significant and strongly correlated risk factors for SWI.  
Interestingly, the administration of antibiotic prophylaxis within 60 minutes of start 
of surgery was not a significant risk factor.  The rate of compliance with local timing 
guidelines for antibiotic prophylaxis was low in both groups (case group 50 % and 
control group 62 %).19 
 
3.3.2. Causative organisms 
 
Coagulase-negative staphylococci or methicillin-sensitive Staphylococcus aureus are 
isolated in the majority of both deep and superficial SWI.19,25,26,27 
 
In some centres, methicillin-resistant Staphylococcus aureus (MRSA) is becoming 
more prevalent.24 Filsoufi et al. found that gram-negative organisms are cultured in 
up to 59 % of cases of mediastinitis, of which the most prevalent isolates were 
Pseudomonas spp., Acinetobacter spp. and Enterobacter spp.24 Culture-negative 














3.4. Antibiotic prophylaxis in paediatric cardiac surgery 
A review of perioperative antibiotic prophylaxis in paediatric cardiac surgery was 
published in 2007.28  The choice of antibiotic, timing of dose and duration of therapy 
of prophylactic antimicrobials has been well debated.  A meta-analysis of four 
placebo-controlled trials established antibiotic prophylaxis as the standard of practice 
in cardiac surgery, and concluded that further placebo-controlled trials would be 
unethical.29  They also showed a reduction of SWI in patients treated with a 
cephalosporin, with a summary odds ratio of 0.51.  Numerous comparisons between 
the first- and second-generation cephalosporins have shown no statistical difference 
between the two groups.28   
Vancomycin appears to be no more effective than the cephalosporins in 
cardiothoracic surgical centres with low levels of MRSA infections.28 Due to its 
side-effect profile, it is suggested that vancomycin be restricted for use in children 
with penicillin or cephalosporin allergies and in areas with a high incidence of 
MRSA.
There is insufficient evidence for the routine use of gentamicin as prophylaxis for 
cardiac surgery.28
Three organisations, the National Surgical Infection Prevention Project (NSIPP), the 
Society of Thoracic Surgeons (STS) and the American College of Cardiology / 
American Heart Association (ACC / AHA) have published guidelines for antibiotic 
prophylaxis in adult cardiac surgery regarding antibiotic choice, dose and duration of 
surgery.30,31,32,33 These adult guidelines recommend cefazolin or cefuroxime as the 
antibiotic of choice for patients without a beta-lactam allergy.  A total duration of 
less than 24 to 48 hours is suggested.  The first dose should be given within 30 to 60 
minutes before surgical incision.  The NSIPP recommends repeated doses 
intraoperatively if surgery is still in progress after two half-lives following the first 











3.4.1. Dosing regimens for cefazolin in paediatric cardiac surgery 
The duration of sternal wound infection prophylaxis is debated.  General consensus 
is that antibiotic prophylaxis should not be for longer than 48 hours following major 
surgery, but some cardiac centres continue prophylaxis until all chest tubes and 
central venous lines are removed.  There are no large randomised prospective trials 
specifically evaluating the duration of prophylaxis in paediatric cardiac surgery.  
Higher doses and prolonged duration of administration of antibiotics is associated 
with higher medical costs and the development of antimicrobial resistance.34 
A prospective observational study of the optimal duration of antibiotic prophylaxis 
for cardiac surgery in adults compared an initial regimen of administering a dose of 
cefazolin at induction of anaesthesia, and one further intraoperative dose, with a new 
regimen of continuing cefazolin for 24 hours postoperatively. 35 This study 
concluded that there was no difference in the 30-day or 6-month mortality between 
the two groups, so increasing the duration of prophylaxis did not result in a 
significant reduction in deep SWI. They also found lower compliance with the new 
24-hour regimen, possibly due to some physicians’ reluctance to give a repeat 
intraoperative dose.  
A randomised prospective study including 838 adult cardiac patients receiving either 
a single dose at induction or a 24-hour treatment, showed that the single-dose 
regimen was associated with an increased incidence of SWI (8.3 %) compared with 
the 24-hour regimen (3.6 %) (p = 0.004).36 They included both superficial and deep 
or organ space SWI. There was no difference in mortality or duration of 
hospitalisation.  
A retrospective review of antibiotic prophylaxis regimens in nearly 4000 paediatric 
cardiac surgical patients analysed three protocols used over a six-year period.37  They 
all received a preoperative dose of cefazolin 50 mg / kg.  Patients in Group 1 
continued to receive cefazolin for as long as the chest drains or central venous 
catheters were present.  Group 2 had antibiotics discontinued after 48 hours, 
regardless of the presence of chest drains or central venous catheters.  Group 3 had 
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of a central line.  This review showed a significantly reduced incidence of SWI in the 
Group 3 (p < 0.05).  The reviewers included both superficial incisional, deep 
incisional as well as mediastinitis / organ space infections, with an incidence of total 
SWI of up to 6.6 % in Group 2, compared with an incidence of 1.7 % in Group 3.  Of 
these infections, 29 % were diagnosed after discharge from hospital.  
 
Another retrospective study was performed to determine whether a decrease in the 
duration of prophylaxis causes an increase in the nosocomial infection rate.38  
194 patients up to the age of 14 were included.  They found that the prolongation of 
prophylaxis for longer than 48 hours increased the nosocomial infection rate.  Also, 
limited prophylaxis to the first 48 hours after surgery did not increase the infection 
rate.  78.5 % of the patients received a cephalosporin in combination with an 
aminoglycoside.  They included all sources of nosocomial sepsis, not limiting the 
study to SWI. 
 
As cefazolin is a time-dependent antibiotic, total time above MIC is the key to its 
successful bactericidal action.6  Continuous infusions of beta-lactam antibiotics have 
been shown to be more effective than intermittent dosing in animal studies.7 A 
prospective, randomised pilot study conducted in 137 adults undergoing coronary 
artery bypass grafting looked at three groups of dosing regimens.39  Group 1 received 
cefazolin 1 g at induction and at end of CPB.  Group 2 received 2 g at induction, 
followed by an infusion of cefazolin at 20 mg / min throughout the surgery.  Group 3 
received 3 g of cefazolin before surgery commenced, followed by a lower infusion 
rate of 15 mg / min throughout surgery.  Serum cefazolin levels were consistently 
higher, at all time points in Group 3 (p < 0.02).  At four of the six time points, Group 
2 had higher levels than Group 1 (p < 0.04).  This study was underpowered to show a 
difference in outcome or incidence of SWI.  There was no incidence of toxicity or 
adverse events as a result of these higher-than-normal doses.   
 
A prospective study investigated perioperative serum levels of cefazolin in 
19 children weighing less than 10 kg undergoing cardiac surgery.40  The children 
received both cefazolin (40 mg / kg) and gentamicin (2 mg / kg) at induction, 











of 2 mg / kg every twelve hours, for 48 hours.  This study showed levels over the 
MIC for potential pathogens (8 mcg / mL) throughout the surgery.  At skin closure, 
some cefazolin levels were as low as 17 mcg / mL.  This study showed decreasing 
serum levels during the CPB period of about 28 %, over an average of 72 minutes of 
CPB duration.  This is in contrast to the work by Miller et al., which suggested that 
the levels should plateau or increasing during CPB due to reduced renal clearance 
and altered protein binding.14  Although this study quoted levels above MIC as 
adequate, some microbiologists are suggesting that four times MIC is a better target 
for effecting 100 % bactericidal action.7  
An earlier study assessing serum levels of cefazolin during CPB used a smaller dose 
of 20 mg / kg (paediatric patients) and 1 g (adult patients), given intramuscularly, an 
hour prior to induction of anaesthesia. 41 This study involved 10 adults and 
10 paediatric patients (7.2 to 28 kg body weight). In the paediatric group, the mean 
serum level was 20 mcg / mL during CPB. The study also demonstrated a drop in 
mean levels after initiation of CPB. Although the study protocol specified levels 
would be measured during sternal closure, there is no specific mention of these 
results. The lowest serum level recorded was 9.8 mcg / mL, well below the currently 
suggested four times MIC.  No reference was made regarding target serum levels.
4. The need for further research
Paediatric data in the field of antimicrobial prophylaxis in cardiac surgery is mostly 
limited to retrospective studies, and small sample sizes.  The altered 
pharmacokinetics and pharmacodynamics within the paediatric population is vastly 
different to that of adults, and extrapolation of adult data is not always appropriate. 
Further research needs to be done in order to determine the most suitable 
antimicrobial prophylaxis regimen for paediatric patients.  The timing of the 
intraoperative doses, as well as the addition of a dose to the priming volume of the 
CPB should be investigated by means of a large prospective randomised study 
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Structured Abstract 
 
Objectives: To determine the plasma concentrations of cefazolin during paediatric 
cardiac surgery involving cardiopulmonary bypass, using our current antibiotic 
prophylactic regimens.  The minimum inhibitory concentration of cefazolin for 
sensitive Staphylococcus spp. is 8 mcg / mL.  Our primary endpoint was to measure 
total intraoperative time spent above four times the minimum inhibitory 
concentration (32 mcg / mL). 
 
Design: A non-interventional, prospective, observational study of current clinical 
practice 
 
Setting: A specialist paediatric teaching hospital 
 
Participants: 22 children with a body weight of less than 25 kilograms, undergoing 
elective cardiac surgery 
 
Interventions:  Patients received standard antibiotic prophylaxis of cefazolin 50 mg / 
kg after induction of anaesthesia, and then further doses as per the 
anaesthesiologist’s normal practice.  Seven subjects received an additional dose to 
the priming volume of the cardiopulmonary bypass pump.  Eight subjects received 
an additional dose after four hours during cardiopulmonary bypass.  Blood samples 
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Measurements and main results: The plasma concentrations of cefazolin were 
measured by liquid chromatography.  In all 22 patients, the plasma levels remained 
above 32mcg / mL for the entire duration of surgery.  In the group who received the 
dose to the priming volume (n = 7), the levels were higher at sternal closure 
(p = 0.04).  
 
Conclusion: Our current antibiotic regimen ensures plasma levels above the target of 
four times the minimum inhibitory concentration for the duration of surgery.  The 
addition of a dose to the priming volume of the bypass pump results in higher levels 




Cefazolin; paediatric cardiac surgery; cardiopulmonary bypass; pharmacokinetics; 
















Postoperative sternal wound infection (SWI) is a considerable cause of morbidity 
and mortality in children following cardiac surgery for congenital heart disease.  The 
incidence of SWI in the paediatric population ranges between 0.2 % and 4.8 %.1,2,3 
Deep SWI (mediastinitis) is associated with a prolonged hospital stay, additional 
operations, increased economic and emotional burden, as well as a mortality of up to 
16 %.4   
 
Prevention of SWI is a vital focus of all paediatric cardiac surgery units.  As 
equivalent international guidelines do not exist for the paediatric population, 
adaptation of the available guidelines for adult cardiac patients is suggested.5 
Emphasis has been placed on appropriate antimicrobial prophylaxis, with three of the 
six Surgical Care Improvement Project (SCIP) guidelines relate specifically to 
antibiotic prophylaxis.  The SCIP was established in 2004 with a mission to ‘reduce 
preventable surgical morbidity and mortality in 25 % by 2010’. 
 
The National Surgical Infection Prevention Project (NSIPP), the Society of Thoracic 
Surgeons (STS) and the American College of Cardiology / American Heart 
Association (ACC / AHA) have published guidelines for antibiotic prophylaxis in 
adult cardiac surgery regarding antibiotic choice, dose and duration of surgery.6,7,8,9 
These adult guidelines recommend cefazolin (a first generation cephalosporin) or 
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patients without an allergy to beta-lactams.  The routine addition of vancomycin may 
be warranted in a centre with a high prevalence of methicillin-resistant 
Staphylococcus aureus (MRSA).6,10 
 
Analysis of breakpoints is helpful in determining an appropriate antimicrobial 
regimen.  A breakpoint is the level of MIC of an antimicrobial agent at which a 
bacterium is deemed either susceptible or resistant to an antibiotic being used.  The 
most recent data on the pharmacokinetic and pharmacodynamic breakpoints of 
cefazolin for Staphylococcus spp. and Enterobacteriaceae spp. was published in 
January 2012.11 If either the MIC of a particular strain or the MIC90 of a group strain 
is found to be at or below this breakpoint, the organism(s) can be considered 
‘susceptible’.  If it is above the breakpoint, it is deemed ‘resistant’.12  The MIC90 is 
the MIC below which 90 % of a group of organisms will show inhibited growth.  
The MIC90 for cefazolin for sensitive Staphylococcus spp. is 8 mcg / mL, for 
intermediately-sensitive Staphylococcus spp. it is 16 mcg / mL and for resistant 
Staphylococcus spp. 32 mcg / mL.  The MIC90 for sensitive Enterobacteriaceae spp. 
is 2 mcg / mL for intermediately-sensitive Enterobacteriaceae spp. 8 mcg / mL and 
for resistant Enterobacteriaceae spp 16 mcg / mL.   
 
As intraoperative contamination can occur at any point during surgery, it has been 
suggested that the dosing regimen should aim for plasma levels over the MIC for 
100 % of the surgical duration as well as for at least a few hours after closure of the 
skin incision.13 Some data suggests that, in order to ensure maximal time-dependent 
killing and prevent the development of resistance, a serum concentration that is at 
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gentamicin levels and postoperative wound infections in colorectal surgical patients, 
the gentamicin plasma concentrations at time of skin closure was the strongest 
independent risk factor for infection.15   
 
The main goal of this study was to evaluate our tertiary paediatric centre’s current 
antibiotic prophylaxis regimens, and ensure the plasma concentrations remain above 




This is a non-interventional observational prospective study of 22 children 
undergoing elective cardiac surgery for congenital heart disease requiring 
cardiopulmonary bypass (CPB) at the Red Cross War Memorial Children’s Hospital 
(RCWMCH) in Cape Town, South Africa.  Ethical approval was obtained from the 
University of Cape Town’s Faculty of Health Science Human Research Ethics 
Committee (HREC Reference: 536 / 2011).  Valid, informed, written consent was 
obtained on the day prior to surgery from the child’s legal guardian. 
 
All the children had a body weight of less than 25 kilograms.  Patients were excluded 
from the study if the expected or actual CPB time was less than 30 minutes, there 
was a history of penicillin or cephalosporin allergy, pre-existing renal or hepatic 
dysfunction was present, exposure to any antimicrobial agent within the previous 
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Patients all received standard perioperative anaesthetic and surgical care, according 
to the current practice at RCWMCH.  Regarding CPB, a Stöckert SIII Mast-Mounted 
Heart Lung Machine with a Stöckert Hemotherm® Heater-Cooler was used, with 
Medtronic® tubing (0.25 inch to 0.375 inch diameter depending on the weight of the 
child).  St Thomas’ Hospital No. 2 cardioplegic solution was used, cooled to 
5 to 8 degrees centigrade.  A loading dose of 20 mL / kg was administered, followed 
by 10 mL / kg every 20 minutes during CPB. 
 
Following induction of general anaesthesia, an initial dose of cefazolin 50 mg / kg of 
body weight was administered as an intravenous infusion over 1 minute, via a 
peripheral intravenous line.  A further dose of cefazolin 50 mg / kg was given four to 
six hours after the initial dose.  Depending on the duration of surgery, this may have 
occurred during CPB or postoperatively on the intensive care unit (ICU).  Two of the 
cardiac anaesthesiologists at our institution routinely add a further dose of cefazolin 
(50 mg / kg) to the priming volume of the CPB circuit.  The administration of this 
priming volume dose was documented and these children were analysed in two 
separate groups.  
 
Blood samples were taken from the intra-arterial catheter placed in either the femoral 
or radial artery after induction of anaesthesia. Most similar studies have used arterial 
samples, as this avoids any possible contamination of the sample by the venous 
administration of the dose.16,17,18  During CPB, the blood sample was taken from the 
CPB circuit.  Each blood sample volume was 0.5 mL.  A maximum of 16 samples 
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In order to perform future pharmacokinetic studies of the effects of CPB on cefazolin 
plasma concentrations, a control population was required.  In the group of children 
who had not had their maximum number of samples taken during surgery, further 
samples were taken postoperatively, following the dose given in ICU.  This was done 
to reduce the variables, which contribute to pharmacokinetic differences between 
individuals as well as to help to determine the potential effects of the CPB.  
 
Blood samples were taken at the following time-points (see Figure 1) 
1. A baseline level (prior to administration of cefazolin) 
2. Three minutes after completion of the initial dose infusion 
3. Sternal incision 
4. Cannulation of the aorta  
5. Initiation of full-flow CPB 
6. Every 30 to 60 minutes during CPB 
7. Prior to the administration of a second dose, if given during CPB 
8. Three minutes after administration of the second dose, if given during CPB 
9. Immediately prior to termination of CPB 
10. 10 to 15 minutes after termination of CPB 
11. Sternal closure (if previous sample taken longer than 10 minutes before 
sternal closure, otherwise just the actual time of sternal closure was recorded) 
12. Trough level prior to the second dose, if given on the ICU 
13. Three minutes after administration of the second dose, if given on the ICU 
14. One to two hours after the second dose in ICU 
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If the estimated CPB time was greater than 120 minutes, samples were taken every 
60 minutes during CPB.   
 
The samples were stored on ice for a maximum of six hours and  then centrifuged for 
ten minutes at a relative centrifugal force of 1 500 g.  The plasma was then stored at 
minus 70 degrees centigrade.  
 
Plasma concentrations of cefazolin were determined using liquid chromatography 
tandem mass spectrometry.  Sample preparation was achieved by protein 
precipitation with acetonitrile containing deuterated nevirapine as the internal 
standard.  Chromatographic separation was performed on a Luna C18 5µ column 
(Phenomenex®) with a mobile phase consisting of acetonitrile and water containing 
0.1 % formic acid (25:75, v / v) delivered at a constant flow rate of 275 mcL / min.  
An AB Sciex® API 4000 mass spectrometer was operated at unit resolution in the 
multiple-reaction-monitoring mode, monitoring the transition of the protonated 
molecular ion m / z 454.9 to the product ions at m / z 232.0 for cefazolin, and the 
protonated molecular ion m / z 270.1 to the product ions m / z 229.1 for the internal 
standard.  
 
The assay was developed and validated for the determination of cefazolin from 
20 mcL human plasma over the concentration range of 0.586 – 110 mcg / mL.  The 
within-day and between-day precision (coefficients of variation) was below 9 % for 
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If not directly measured, prediction of the concentration at the time of sternal closure 
was done using Microsoft Excel®.  The data were first visually inspected to ascertain 
that the pharmacokinetic profile was in the log-linear elimination phase around the 
times of sternal incision and closure, and then a linear interpolation on the log-
transformed data was used to predict the concentration. 
 
Statistical analysis was done using Stata® data analysis and statistical software.  A 
histogram was used for each variable to test for normality, revealing mostly skewed 
data.  When two groups were compared, the non-parametric Mann-Whitney U test 
was applied.  A p-value of less than 0.05 was considered to be statistically 




The demographic data for the 22 subjects is presented in Table 1 and the types of 
operations performed are depicted in Table 2.  All 22 children fulfilled the inclusion 
and exclusion criteria.  Two additional cases were enrolled into the study.  One case 
was withdrawn due to an unexpectedly short CPB time of 13 minutes.  The other 
subject was given antibiotics for a concurrent infection on the day prior to surgery. 
In 19 of the subjects, a plasma concentration at the time of sternal closure was 
calculated from the log-linear elimination phase study.  An actual sample was not 
taken in these cases because the sternal closure was performed very soon after 
termination of CPB, and a sample had already been taken within ten minutes of 
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All of the patients, regardless of intraoperative re-dosing or the addition of a dose in 
the priming volume of the pump, had 100 % of the measured and calculated plasma 
concentrations over 32 mcg / mL for the duration of surgery.  This represents the 
target concentration of four times the MIC for sensitive Staphylococcus spp.  This is 
also well above four times the MIC for the sensitive Enterobacteriaceae spp. 
(8 mcg / mL). (Figure 2) 
 
All of the subjects received the initial dose of cefazolin within 30 to 60 minutes of 
skin incision, which is in keeping with the international adult guidelines.6,7,8,9 
 
Seven patients (31.8 %) received a dose of cefazolin to the priming volume of the 
pump (Group 1) and fifteen patients (69.2 %) did not receive a dose to the priming 
volume (Group 2).  In Group 1, six patients received an additional dose of cefazolin 
during CPB (four hours after the initial dose).  In Group 2, only two patients received 
an additional dose during surgery.  Both the CPB duration, and total operating time 
were significantly longer in Group 1 (p = 0.001) (see Table 3).  The median plasma 
concentrations at sternal closure were higher in Group 1 compared to Group 2 
(113 mcg / mL vs. 64 mcg / mL, p = 0.04), although both were above the target of 
32 mcg / mL.  (Figure 3) 
In those patients who had a total CPB time of less than 120 minutes (n = 11), the 
plasma concentration of cefazolin was significantly lower at sternal closure, 
compared to those with longer CPB times (64 mcg / mL vs. 113 mcg / mL, p = 0.04).  
Of the group with a longer CPB group, 6 of the 11 subjects received a dose to the 
priming volume of the pump as well as an additional dose during CPB.  In the group 











In subjects where the lowest recorded temperature was below 30 degrees centigrade 
(n = 11), the plasma levels at sternal closure were significantly higher (p = 0.02).  In 
this lower temperature group, six of the eleven children received a dose to the 
priming volume.  
Three patients developed sternal wound infections (13 %). One of these cultured 
MRSA in a pus swab, while the other two were culture-negative. Two of the 
22 patients died postoperatively: one died from non-infective cardiac causes, while 
another died from mediastinitis secondary to MRSA, twelve days postoperatively.  
Discussion 
Cardiopulmonary bypass can affect the pharmacokinetics and pharmacodynamics of 
drugs for a variety of reasons. The main factors are an increased volume of 
distribution (with resultant haemodilution), altered protein binding, decreased 
elimination, reduced organ perfusion and hypothermia.19 With prolonged CPB 
duration and the lower core body temperatures that occur during the process, these 
effects will be exaggerated. In order to maintain plasma levels for the duration of 
surgery, many cardiac anaesthesiologists prime the CPB pump with cefazolin and 
give additional doses intraoperatively. The correct dose, and regimen required to 
maintain these levels in the paediatric population are still under debate, as is the 
duration of perioperative prophylaxis.10 Plasma concentrations of at least four times 
the MIC for susceptible bacteria should be maintained for the intraoperative period, 
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The first dose should be given within 30 to 60 minutes before surgical incision.  The 
NSIPP recommends repeated intraoperative doses if the operation is still in progress 
after two half-lives following the first dose, while the National Institute for Health 
and Clinical Excellence (NICE) suggests re-dosing in surgical procedures lasting 
longer than the half-life of the antibiotic used.20  The STS recommends a second 
dose every three to four hours during surgery.7 A total duration of postoperative 
prophylaxis of less than 48 hours is suggested.  Higher doses and prolonged duration 
of administration of antibiotics is associated with higher medical costs and the 
development of antimicrobial resistance.21  The only published cases of possible 
cefazolin toxicity suggested that high cerebrospinal fluid concentrations (CSF) of 
cefazolin (34 – 106 mcg / mL) were associated with seizures in three adult patients.22 
No reference range exists for CSF cefazolin concentrations, and the correlated serum 
levels were 360 – 1000 mcg / mL.  The highest plasma level in our study was a peak 
level of 722 mcg / mL following a second dose during CPB. This might hold clinical 
relevance, as seizure activity will be masked by general anaesthesia. 
 
The usual serum half-life of cefazolin is 108 minutes (1.8 hours).23  This can be 
prolonged during CPB owing to reduced renal clearance and increased total body 
distribution.24  Most antibiotic prophylaxis guidelines recommend re-dosing at three 
to four hour intervals.  In a retrospective study of over 1500 patients undergoing 
cardiac surgery lasting longer that 240 minutes, the overall risk of SWI was similar 
in those patients who received additional intraoperative doses and those who did not.  
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Overall, the authors calculated a potential 16 % reduction in risk of SWI if a strategy 
of re-dosing in all procedures lasting than 240 minutes was employed.25   
 
The effect of hypothermia on serum cefazolin levels was investigated in a 
prospective study by Caffarelli et al.26 This study found that serum cefazolin levels 
were not affected by a CPB duration of less than 120 minutes with mild to moderate 
hypothermia.  In cases requiring CPB times of longer than 120 minutes, the plasma 
levels dropped to ineffective therapeutic levels in 50 % of patients.  Profound 
hypothermic circulatory arrest appeared to have a slightly protective effect on the 
serum levels.  Although these cases also had prolonged CPB times, only 10 % of 
patients had a sub-therapeutic plasma level.  This is possibly due to the delayed renal 
excretion that can occur at low body temperatures.   
 
Although all subjects had plasma concentrations above 32 mcg / mL at sternal 
closure, the levels in Group 1 were higher.  These children also had a longer duration 
of CPB and overall surgical time.  The two clinicians, who routinely add a dose of 
cefazolin to the priming volume of the pump, are the more senior and experienced 
paediatric cardiac anaesthesiologists at RCWMCH.  These cases may have been 
allocated to them as they were the more challenging cases, with an expected 
prolonged CPB time.  Six of the seven cases in this group also received an additional 
dose during CPB, four hours after the initial dose.  The increased plasma levels at 
sternal closure were therefore due to a combination of the priming dose and the 
additional dose during CPB.  As only two of the fifteen cases in Group 2 received an 
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There are a few notable limitations to this study.  Due to the small sample size, the 
study was underpowered to comment on the efficacy of the antibiotic prophylaxis.  
We also failed to reach statistical significance with most comparisons.  There are no 
clear MIC targets for antibiotic prophylaxis, as most studies are specifically aimed at 
therapeutic goals.  We chose the upper limit of suggested targets from recent 
literature, of four times MIC for 100 % of the surgical time, but other similar studies 
have aimed at levels over MIC for 40 to 50 % of the time.12,13  
 
As this was a non-interventional, observational study, there was no randomisation of 
patients.  In some cases, a dose of cefazolin was added to the priming volume, and 
further intraoperative administration was left to the responsible anaesthesiologist.  
This led to unequal group distribution. 
 
The total cefazolin plasma concentration was measured in this study.  As it is the free 
fraction that is available to bind at the bacterial cell membrane, any alterations in the 
protein binding will also affect this level.  This is not taken into account in this study. 
 
To determine the effects of CPB on the plasma concentrations, further 
pharmacokinetic analysis of the data is planned,.  Most of the subjects had blood 
samples taken postoperatively on ICU, which will then serve as a control for this 
further work. 
 
In conclusion, the current antibiotic prophylaxis regimen at our institution provides 










	   56 
additional dose to the priming volume of the pump, and intraoperative re-dosing in 
cases that have a longer duration of CPB, result in higher plasma levels at the time of 
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Figure 2: Box plot showing plasma concentrations of cefazolin at 
intraoperative time-points (Bold horizontal line represents 32 mcg / mL, 
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Figure 3: Box plots showing the difference in plasma concentrations of 
cefazolin between Group 1 (n = 7) and Group 2 (n = 15) (Bold horizontal 




















Peak Sternal incision Pre−CPB Full flow CPB Off CPB Sternal Closure
Peak Sternal incision Pre−CPB Full flow CPB Off CPB Sternal Closure
Group 2: No dose to CPB Priming Volume





































Age (months) 19.5 11.0 – 46.0 1.0 94 
Weight (kg) 8.7 6.0 – 12.5 2.0 21.6 











25.1 – 32.2 
33.4 – 64.4 









165 139 – 337 83 400 
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Table 2: Type of cardiac surgery performed (n = 22) 
 
Surgery performed Number of cases (n = 22) 
 
Repair of ventricular septal defect 
 
5 
Repair of transposition of the great arteries 4 
Repair of atrioventricular septal defect 3 
Repair of pulmonary atresia 2 
Repair of Tetralogy of Fallot 2 
Augmentation of right ventricular outflow tract 2 
Repair of atrial septal defect 1 
Ross Procedure for aortic regurgitation 1 
Repair of total anomalous pulmonary venous 
drainage 
1 
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Table 3: Comparison of Group 1 (dose to priming volume) vs. Group 2 
(no dose to priming volume) 
 




(p25 – p75) 
Group 1  
(n = 7) 
 
CPB time (mins) 
Total surgical time (mins) 
Plasma concentration at sternal 




165 – 275 
230 – 382 
104 – 144 
 
Group 2  
(n = 15) 
 
CPB time (mins) 
Total surgical time (mins) 
Plasma concentration at sternal 






72 – 125 
129 – 172 
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Data collection form 
  
Patient No: ___________ 
 
Date of surgery: _________________ 
 
Primary cardiac diagnosis: ______________________________________________ 
 
Operation performed: __________________________________________________ 
 
Age:  __________  Gender: ______________ 
Weight (kg): __________  Ethnic group: __________ 
Height (cm): __________   Cefazolin dose (50 mg / kg):  ______________ 
 










Any antibiotics in past week? ____________________________________________ 
 



















K:  ______________ 
Urea:  ______________ 
Creat:  ______________ 
    
 
Estimated GFR (Schwartz formula) (mL/min/1.73m2) =  _________________ 
[k x height (cm)/[Serum creatinine (mmol/l)]*88.402 
Children < 1 year of age: Preterm baby k=0.33, Fullterm baby k=0.45  
1-12 years of age: k = 0.55 
 
Peripheral IV cannula:  ______________________ 
Central venous catheter:  ______________________ 
Intra-arterial catheter:  ______________________ 
 
Any evidence of sternal infection in first 2 weeks post operatively? (Y/N) _________ 
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Times and Events 
 
Event Time Sample Further doses and time 
Induction of anaesthesia    
Baseline sample  00  
Dose 1    
Peak (3 mins)  01  
Sternal incision  02  
Pre-CPB (aortic cannulation)  03  
Full Flow CPB  04  
CPB  05  
CPB    
CPB    
CPB    
CPB    
CPB    
CPB    
CPB    
CPB    
CPB    
CPB    
CPB    
CPB    
Off CPB    
Sternal Closure    
CPB residual  UF Volume: 
Trough level    
Dose (ICU)    
Sample 1    
Sample 2    
Sample 3    
 
Dose given to CPB priming? (Y/N)   ______________ 
Type of cardioplegia used:   ______________ 
Total volume of cardioplegia used:  ______________ 
Total CPB time (mins):   ______________ 
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Fluid given during surgery 
 
Crystalloid   Type of fluid    Volume  
 
Pre-CPB:    ______________   ___________  
   ______________   ___________  
During CPB:    ______________   ___________  
    ______________   ___________  
Post-CPB:    ______________   ___________  
   ______________   ___________  
 
Colloid   Type of fluid    Volume 
 
Pre-CPB:    ______________   ___________  
    ______________   ___________  
During CPB:    ______________   ___________  
   ______________   ___________  
Post-CPB:    ______________   ___________  
   ______________   ___________  
 
Blood products  Type of fluid    Volume 
 
Pre-CPB:    ______________   ___________  
    ______________   ___________  
During CPB:    ______________   ___________  
    ______________   ___________  
Post-CPB:    ______________   ___________  
    ______________   ___________  
 
 
Priming fluid and volume CPB: _________________________________ 
 







Time:             
             
pH             
BE             
HCO3             
Lactate             
Hb             
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Drugs given during surgery 
 
 Drug Dose Time given 
Pre CPB    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
During CPB    
    
    
    
    
    
    
    
    
    
Post CPB    
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Parent Information Sheet 
 
Your child is requiring open-heart surgery.  During the surgery your child will 
require a heart bypass machine.  This machine does the work of the heart and lungs 
while the surgeons are operating on the heart.  Blood circulates through the machine 
and then back into the child’s body. 
 
We routinely give a dose of antibiotics at the start of the operation to prevent any 
infection in the wound afterwards.  We want to make sure that the levels of 
antibiotics in the blood remain adequate for the duration of surgery.  There is not 
much available literature regarding these levels in children. 
 
This will involve taking blood samples during surgery and measuring the levels of 
antibiotics.  The blood will be taken from a special catheter in the artery, which is 
routinely placed while the child is sleeping before the surgery starts.  A maximum of 
16 samples will be taken during the surgery, which will be less than 10ml in total of 
blood (equivalent of two teaspoons).  This will not affect your child’s recovery from 
surgery. 
 
There will be no direct benefit to the children who participate in the study. 
 
Participating in the study will not affect your child’s care in any way.  Once you 
have given consent to your child being included in the study, you may withdraw 
consent at any time and this will also not affect your child’s care. 
 
The results from this study can help us to ensure we are giving the correct dose of 
antibiotics.  The appropriate Ethics Committee has approved this study. 
 
If you require any further information please feel free to contact me. 
 
Chief Researcher: 
Dr Alex Dresner 
Anaesthetic Registrar 
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CONSENT TO INCLUSION OF CHILD IN CEFAZOLIN STUDY 
 
Affix hospital sticker here (if available) 
Name of patient: _____________________ 
Hospital no.: ______________ 
Date of birth: ______________ 
 
I ______________________ (parent/guardian) hereby consent to the inclusion of my 
child _________________________ (child’s name) in the cefazolin plasma 
concentrations study in cardiac surgery. 
 
I have received written information on the study.  Yes    No      
The study has been fully explained to me.    Yes    No      
I have had my questions answered adequately.  Yes    No      
I give permission for my child’s blood samples to be  
stored and analysed at a later date    Yes    No     
 
I have the right to withdraw consent at any time and my child’s management will not 
be compromised in any way. 
 
Full name of parent/guardian: ______________________ 
Relationship to child:  ____________________________ 
Signature of parent/guardian: ______________________ 
Date: _________________ 
 
Full name of witness: ____________________________ 
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Inligtingstuk vir ouers 
 
U kind benodig ope-hart chirurgie.  Tydens die prosedure sal u kind ‘n hart 
omleidingsmasjien benodig.  Die masjien doen die werk van die hart en longe terwyl 
die chirurg op die hart opereer.  Bloed sirkuleer deur die masjien en dan terug na die 
kind se liggaam. 
 
Ons gee roetineweg ‘n dosis antibiotika aan die begin van die operasie om infeksie in 
die wond na die tyd te voorkom.  Ons wil seker maak dat die antibiotika se vlakke in 
die bloed voldoende bly vir die volle durasie van die chirurgie.  Daar is nie baie 
inligting aangaande hierdie vlakke in kinders beskikbaar nie. 
 
Dit behels dat daar gedurende die operasie bloedmonsters geneem sal word om die 
vlak van die antibiotika te toets.  Die bloed sal uit ‘n spesiale kateter in ‘n aar 
geneem word.  Hierdie kateter word roetineweg ingeplaas voor die chirurgie begin, 
maar na die kind reeds slaap.  ‘n Maksimum van 16 monsters sal gedurende die 
chirurgie geneem word.  Die totale volume is minder as 10ml bloed (gelykstaande 
aan twee teelepels).  Dit sal nie u kind se herstel na die chirurgie beïnvloed nie. 
 
Daar sal geen direkte voordeel wees vir kinders wat aan hierdie studie deelneem nie. 
 
Deelname aan die studie sal nie die sorg wat u kind kry op enige manier beïnvloed 
nie.  Nadat u toestemming gegee het vir deelname aan die studie, mag u toestemming 
onttrek op enige stadium.  Dit sal ook nie die sorg wat u kind kry op enige manier 
beïnvloed nie. 
 
Die uitslae van die studies sal ons help om te verseker dat die korrekte dosis 
antibiotika gegee word.  Die toepaslike Etiekkomitee het hierdie studie goedgekeur. 
 
Indien u verdere inligting benodig, is u welkom om my te kontak. 
 
Hoofnavorser : 
Dr Alex Dresner (Kliniese Assistent in Narkose) 
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TOESTEMMINGSVORM VIR INSLUITING VAN KIND BY 
CEFAZOLIN STUDIE 
 
Plak hospitaalplakker hier (indien beskikbaar) 




Ek ______________________ (ouer/voog) gee hiermee my toestemming tot die 
insluiting van my kind _________________________ (kind se naam) in die 
cefazolin-plasmakonsentrasie studie tydens hartchirurgie.  
 
Ek het geskrewe inligting oor die studie ontvang.  Ja     Nee     
Die studie is volledig aan my verduidelik.    Ja     Nee   
My vrae is voldoende beantwoord.    Ja     Nee   
Ek gee toestemming dat my kind se bloedmonsters 
gestoor mag word en by ‘n latere geleentheid geänaliseer 
mag word.       Ja     Nee   
 
Ek het die reg om toestemming op enige stadium te onttrek sonder dat my kind se 
behandeling op enige manier benadeel sal word. 
 
Volle naam van ouer/voog: ______________________ 
Verhouding tot kind: ___________________________ 
Handtekening van ouer/voog: ____________________ 
Datum: _________________ 
 
Volle naam van getuie: _________________________ 
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Iphepha lengcaciso eya kubazali 
 
Umntwana wakho kuya kufuneka enziwe utyando entliziyweni.  Ngexesha lotyando 
kuza kufuneka umntwana wakho abe nomatshini wotyando lwentliziyo othintela 
igazi lingagqithi kule ndawo inengxaki xa liphuma emzimbeni (ibypass machine).  
Lo matshini wenza umsebenzi wentliziyo nowemiphunga ngeli xesha esenza utyando 
entliziyweni ugqirha.  IGazi lijikeleza kulo matshini ze liphinde libuyele emzimbeni 
womntwana. 
 
Ngokommiselo sisinika umlinganiselo othile wesibulala-zintsholongwane isigulane 
ngaphambi kokuqalisa utyando, ukuthintela ukusuleleka kwenxeba ziintsholongwane 
emva kotyando.  Sifuna ukuqinisekisa ukuba ubungakanani besibulala 
zintsholongwane egazini uhlala ungofanelekileyo de lugqitywe utyando. 
 
Oku kubandakanya nokutsalwa kweesampulu zegazi ngexesha lotyando nokujongwa 
kobungakanani besibulala-zintsholongwane.  Igazi elo liye litsalwe ngekhathetha 
kumthambo ongunothumela (i-athari), eye ithi ngokommiselo ifakwe emntwaneni 
ngexesha aleleyo ngaphambi kokuqaliswa kotyando.  Umlinganiselo ongowona 
uphezulu  weesampulu ezili-16 zegazi ziya kutsalwa xa kutyandwa, kodwa loo 
mlinganiselo uya kuba ngaphantsi kwe-10ml uwonke (ulingane neetispuni ezimbini).  
Akukho nto iya kuphazamisana nokuchacha komntwana wakho emva kotyando. 
 
Iziphumo zolu phando ziya kusinceda ukuqinisekisa ukuba sisineke umlinganiselo 
ochanekileyo wesibulala-zintsholongwane isigulane.  IKomiti ejongene neeNkqubo 
eziseSikweni ikwamkele oku. 
 
Ukuba ufuna iingcombolo ezithe vetshe unganditsalela ngokukhululekileyo. 
 
IGosa loPhando eliyiNtloko: 
 
Gqr Alex Dresner 
IRejistra ye-Anesthethikhi 
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IMVUMELWANO YOKUBANDAKANYWA KOMNTWANA 
KUPHANDO LWE- CEFAZOLIN 
 
Ncamathelisa isitika saseSibhedlele apha (ukuba 
sikhona) 
Igama lesigulane: _____________________ 
INomb. yefayili yaseSibhedlele: ______________ 
Umhla wokuzalwa:______________ 
 
Mna ______________________ (umzali/umgcini-mntwana) ndinika imvume 
yokuba abandakanywe umntwana wam  u_________________________ (igama 
lomntwana) kuphando olusebenzisa into ekuthiwa yi-cefazolin plasma xa kusenziwa 
utyando lwentliziyo. 
 
Ndifumene imbalelwano endazisa ngolu phando. Ewe   Hayi  
Ndicaciselwe ngokupheleleyo ngolu phando. Ewe   Hayi  
Ndiphendulwe ngokwanelisayo kuyo yonke imibuzo ebendinayo.  Ewe     Hayi   
Ndinikezela imvume yokuba elinye igazi lomntwana wam ligcinwe lijongisiswe 
ngelinye ixesha.        Ewe   Hayi  
 
Ndinelungelo lokumrhoxisa nangaliphi ixesha umntwana wam kodwa oko kungayi 
kuyichaphazela inkqubo yokunyangwa kwakhe nangayiphi na indlela. 
 
Igama elipheleleyo lomzali/lomondli: ______________________ 
Ulwalamano nomntwana:  _____________________________ 
Kutyikitya umzali/umondli: ______________________________ 
Umhla: _________________ 
 
Igama elipheleleyo lengqina: _____________________________ 
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Notes for authors (from http://www.jcardioanesthesia.com/authorinfo) 
 
 
Journal of Cardiothoracic and Vascular Anesthesia 
 
The Journal of Cardiothoracic and Vascular Anesthesia will consider for publication 
suitable articles on all topics related to anesthesia for cardiac, vascular, and thoracic 
surgery. The scope of this Journal is broad and seeks to consolidate all material 
pertinent to cardiothoracic anesthesiology, including topics from critical care 
medicine, pharmacology, monitoring, perfusion technology, internal medicine, 
surgery, and transplantation.   Articles, editorials, letters to the Editor, and other text 
material in the Journal represent the opinion of the authors and do not necessarily 
reflect the opinion of the Editor, Editorial Board, or Publisher. The Editors and 
Publisher deny any responsibility or liability for statements and opinions expressed 
by the authors. Neither the Editor nor the Publisher guarantees, warrants, or endorses 
any product or service advertised in this publication, nor do they guarantee any claim 
made by the manufacturer of such product or service.   Authors submitting a 
manuscript do so with the understanding that if it is accepted for publication, 
copyright of the article, including the right to reproduce the article in all forms and 
media, shall be assigned exclusively to the Publisher. Following acceptance for 
publication, in order to comply with United States copyright law and the 
requirements of the insurance carrier, the Publisher will require authors of accepted 
manuscripts and letters to sign a copyright release form.    
 
SUBMISSION   All submissions must be directed to our web site:  
http://ees.elsevier.com/jcva. Offline submission is not permitted, unless requested 
by the Editorial Office. On the home page you will find links not only to this Guide, 
but also to a Tutorial for Authors, Artwork Guidelines, and general information on 
the Journal.   First-time Corresponding Authors can register from the home page by 
clicking on the register link. You will receive e-mails guiding you on the basic 
information for submitting a manuscript. Each page of the web site during the review 
process contains important information for that step. The Editorial Office will send 
by e-mail only to the Corresponding Author all communications related to the 
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publication.   Detailed information on submissions is provided below. Further 
inquiries and information may be directed to the Editorial Office at: 
dwalk@louisville.edu.    
 
EDITORIAL POLICIES   Manuscripts are accepted for consideration on the 
condition that they are contributed solely to the Journal of Cardiothoracic and 
Vascular Anesthesia. No substantial part of a paper may have been published 
elsewhere, except for a scientific abstract.   Manuscripts will be reviewed by the 
Editor in Chief, Section Editors, members of the Editorial Board, and appropriate 
guest reviewers. Acceptance of a paper for publication is based on the originality and 
quality of the observation or investigation and the clarity of the presentation. 
Clinically relevant material is especially desirable. Good English usage is an 
essential prerequisite for consideration of the paper.   In all cases the authors must 
accept the responsibility of conforming to the instructions in the sections below. 
Submissions must conform fully before reviewers will be assigned. Substantial non-
conformity may result in outright rejection.   If a submitted article is accepted for 
publication, editorial revisions may be made to aid clarity and understanding without 
altering the meaning.    
 
Electronic-only Publication. Letters to the Editor, the Cardiac Calendar, and 
selected articles from other sections (e.g., Case Reports, Diagnostic Dilemmas, and 
E-Challenges) are published E-ONLY. Like print articles, E-only articles will be 
indexed in Medline and elsewhere and will be included on the print issue's Table of 
Contents.    
 
Experimentation subjects. Papers reporting human experimentation will be 
reviewed in accordance with the precepts established by the Helsinki Declaration 
(available at http://www.wma.net/en/30publications/10policies/b3/). Such papers 
must include a statement that human investigations were performed after approval by 
a local Human Investigations Committee and after obtaining informed consent from 
a patient or other responsible individuals. All experimental work with animals must 
conform to American Physiological Society Guiding Principles for the Care and Use 
of Vertebrate Animals in Research and Training (http://www.the-
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Article types. The following may be submitted: Original Research Articles, Case 
Reports, Review Articles, Emerging Technology Reviews, E-Challenges and 
Clinical Decisions, Case Conferences, Pro and Con Articles, Diagnostic Dilemmas, 
Special Articles (those not easily suited to another type), and Correspondence (letters 
to the Editor). Cardiac Anesthesia Fellows Education (CAFE) articles may be 
submitted by cardiac fellows and their mentors. The CAFE section is devoted to 
developing the clinical and publication skills of fellows. Articles for this section may 
be submitted as any of the above article types and may be augmented by expert 
commentaries. Case Conferences should be augmented by expert commentaries. 
Potential authors are invited to e-mail the Editorial Office to contact Editor in regard 
to interest in a proposed submission.    
 
DETAILS ON ARTICLE TYPES   For examples of all article types, see any 
recent issue of the Journal.   For all submissions, each table, figure, or video/audio 
clip is to be included only as a separate Table, Figure, or Video/Audio Clip 
document, and is not to be placed in the Manuscript (main text) document. Video 
stills must be submitted as Figures.   
 
Original Research Articles. This article type requires 4 documents: Cover Letter, 
Title Page, Structured Abstract, and Manuscript.  
The Structured Abstract is limited to 250 words (including section headings). The 
abstract should consist of 7 paragraphs:  1. Objective(s): What scientific question 
was the study designed to answer?  2. Design: A phrase describing whether a study is 
prospective, randomized, blinded, retrospective, etc.  3. Setting: Type of hospital or 
laboratory; university or community setting; single or multi-institutional.  4. 
Participants: Patients, volunteers, animals.  5. Interventions: What interventions were 
done to the participants?  6. Measurements and Main Results: How was the outcome 
of the intervention(s) assessed? What were the major finding(s) of interest?  7. 
Conclusions: What conclusion(s) may be reasonably drawn from the results of the 
study?   Following these 7 paragraphs, repeat the list of Key Words that you have 
uploaded onto the Key Word page. No references or abbreviations should be used in 
the abstract. The name or location of the authors institution should not be revealed.  
The Manuscript document must have 4 identified sections: Introduction, Methods, 
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included in the last part of the Methods section. The name or location of the authors' 
institution should not be revealed in this document.    
 
Case Reports. This article type requires 4 documents: Cover Letter, Title Page, 
Summary, and Manuscript. The Manuscript document should begin with a short 
introduction to the clinical context of the case and follow with 2 identified sections: 
Case Report and Discussion. A 1-paragraph summary should complete the article. In 
most situations the introduction and final summary can be the basis for the Summary 
item.    
 
Case Conferences. These articles are handled by a Section Editor for Case 
Conferences. Some offline communication between authors and editors may be 
required. 
• A Case Conference comprises a Case Report with a Discussion and one or more 
experts commentaries that provide input from related specialties and/or 
viewpoint(s) on anesthetic or intensive care management of the case. 
• A commentator needs to provide his or her full name, degrees, affiliation, and e-
mail address. Commentators will be listed as authors. 
• Figures, video clips, tables, and references from the case authors and commentators 
are desirable to expand the teaching value of the case. Follow the guidelines below 
for preparing figures, video clips, tables, and references. 
• The final version of the Case Conference will have its references compiled into a 
single consecutively numbered list. 
 
 
Review Articles. Review articles may be invited by a Section Editor, but invitation 
is not necessary for full consideration. This article type requires 3 documents: Cover 
Letter, Title Page, and Manuscript. The scope and purpose of the review must be 
clearly defined and accomplished in the Manuscript document. Authors are 
encouraged to provide relevant table, figure, and video clip documents.  
 
Diagnostic Dilemmas. This cogent article type is in two parts. First, it presents a 
case with difficult diagnosis, usually resulting from preliminary graphic evidence. 
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interpretation of further imaging techniques or other investigation is provided to 
resolve the dilemma. High quality figures and/or video clips are vital for these 
submissions.  
 
Letters to the Editor. A Cover Letter and a Title Page are needed separate from the 
Letter (Manuscript) item. The Letter to the Editor should be double-spaced, brief, 
and concisely focused. Cited works must have full, accurate references. Figures, 
video clips, and tables may be included. Letters to the Editor will be published only 
online.  
 
MANUSCRIPT DETAILS  
• All documents (except figures) should be prepared in Microsoft Word for Windows 
or a fully compatible program, not in .pdf or any graphic format.  
• Manuscripts must be double-spaced throughout the document on page sizes 8½ x 
11 inches or A4. A margin of about 1 inch (2.5 cm) should be provided on all sides. 
All type should be 11-13 points in size, except as appropriate in tables and figures. 
Page numbers are required on Manuscript (main text) documents. Landscape format 
is acceptable as needed to display tables or figures to advantage.  
• Word limits are not imposed on any manuscript types, but all papers should be 
concise, yet complete.  
• All required or optional items for a submission are identified on the Attach Files 
page on the online submission form. Every table, figure, or video clip requires a 
separate electronic file; the "Description" column on the Attach Files page should 
provide the textual reference (e.g., 'Table 3'); this column is fully editable.  
• No document can be submitted "offline."  
• Use generic drug names throughout. Brand names may be inserted in parentheses 
following the generic names.  
• The name and city/state/country of a drug or technology manufacturer must be 
included after the name of the product.  
• The author(s) or the name or geographical location of an author's 
institution(s) must not be identified in the text, header, or footer in the 
submission except on the Title Page and the Cover Letter.  













Online submission requires that the submitted material be uploaded in several 
separate files. Online instructions will clarify what files are required. Details on 
preparation of file types follow.  
1. A Cover Letter addressed to the Editor in Chief. The letter must include at the 
end a list of all authors as if for signature. Cover letters scanned from official 
letterhead with all signatures are strongly encouraged. The cover letter must state 
that the authors agree with and are responsible for the data presented. The letter 
should also describe or deny any potential conflicts of interest including commercial 
relationships such as consultation and equity interests. 
2. Title page with (a) title of paper; (b) authors' full names with advanced degrees; 
(c) name(s) and geographical location of institution(s) in which work was done; (d) 
description of research support, if any; (e) information on the corresponding author: 
full name and advanced degrees, a reliable e-mail address, complete street address 
(not only P.O. box), telephone and fax numbers, and (f) any personal 
acknowledgements. 
3. For an Original Research article, a Structured Abstract; but for a Case 
Report, a Summary (max. 200 words to indicate the clinical context and 
significance of the case, recapitulate the essential features, its outcome, and likely 
consequences for further study or clinical practice). A Structured Abstract will be 
published; a Summary is not published but is circulated to invited reviewers. 
4. Manuscript/main text The Figure Legend list should be provided after the list of
references and double-spaced. The Figures should be followed by Video Clips in this
list. Each legend should include a title, notes to gloss abbreviations, and a permission
statement for use of any copyrighted materials. Titles and notes for tables should not
be in this list. Automatic reference systems may be used but are not required. The
first reference to each source must be in Arabic numerical order. The reference list at
the end of the article must also be in numerical order. The list headed
"REFERENCES" should begin on a new page of the Manuscript document and be
double-spaced. Use NLM-recognized title abbreviations for periodicals throughout
as available listed online at http://www.ncbi.nlm.nih.gov/journals (based on those
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supplements, and letters to editors must be identified as such. Inclusive page 
numbers of references are required. Online references should be integrated 
numerically with the other media in the References list; do not submit them 
parenthetically or as footnotes.  
5. Tables. A separate file is required for each table, including its number and title at 
the top and any notes at the end. The notes should provide definition of abbreviations 
used in the table and permission notices for use of copyrighted materials. Tables 
should be formatted as Microsoft Word tables or Excel spread sheets, not in any 
graphic format. A table may be continued on multiple pages if necessary; do not 
repeat column headers on the additional pages.  
6. Figures. A separate file is required for each figure, except for figures cited 
together and preferably to be seen adjacently (a-b etc.) It is strongly preferred that 
figures be submitted in .tif (300 dpi), .eps, or .pdf format. The highest possible 
quality is expected. Authors are responsible to meet the graphic standards in 
Publisher's Author Artwork Instructions 
(http://www.elsevier.com/artworkinstructions). A link to these Instructions is also 
provided on the Journal's home page. Authors are strongly advised to consult 
these Instructions for detailed in ormation before preparing figures. The 
Publisher automatically provides for every submission or revision an Artwork 
Quality Assessment to inform authors of any likely problems with their figures. 
Figures not properly prepared will be returned to the contributor for revision or will 
be reworked with the cost charged to the contributor. Color figures are acceptable for 
papers dealing with color imaging; however, as color printing is costly, it will be 
used at the discretion of the Editor. Color used in bar, line, and pie graphs is 
discouraged; please substitute distinct shades of gray and /or patterned lines and 
shapes. If color images are to be reproduced in black and white, the contributor 
should submit the prints in black and white for best results.  
7. Video/audio clips. The preferred movie/video format is .mpg, and the preferred 
audio format is .mp3. For additional information, follow the link to Author Artwork 














	   87 
SAMPLE REFERENCES  
Journal article, one to three authors 
1. Beutler E: The effect of methemoglobin formation on sickle cell disease. J Clin 
Invest 40:1856-1858, 1961 
2. Karpatkin S, Smith K, Charmatz A: Heterogeneity of human platelets. III. 
Glycogen metabolism in platelets of different sizes. Br J Haematol 19:135-137, 1970  
 
Journal article, four or more authors 
3. Golomb HM, Vardiman J, Sweet DL, et al: Hairy cell leukemia: Evidence for the 
existence of a spectrum of functional capabilities. Br J Haematol 38:161-162, 1968  
 
Journal article in press 
4. O'Malley JE, Eisenberg L: The hyperkinetic syndrome. Semin Psychiatry (in 
press) 
(Note: A copy of the in-press article must be included as a Supplementary 
Manuscript file, described as "In-press, Reference [#].")  
 
Complete book 
5. Lillie RD: Histopathologic Technic and Practical Histochemistry (ed 4). New 
York, NY, Blakiston, 1965, pp 39-41  
 
Chapter of book 
6. Moore G, Minowada J: Human hemopoietic cell lines: A progress report, in 
Farnes P (ed): Hemic Cells in Vitro, vol 4. Baltimore, MD, Williams & Wilkins, 
1969, pp 100-105  
 
Chapter of book that is part of published meeting 
7. Hatvg JB, Kunkel HG, Gedde-Dahl T Jr: Genetic studies of the heavy chain sub-
groups of gamma globulin, in Killander J (ed): Gamma Globulins, Proceedings of the 
Third Nobel Symposium. New York, NY, Wiley, 1967, pp 19-26  
 
Chapter of book that is part of unpublished meeting 
8. Polliak A: A morphologic study of the lymphoproliferative lesions induced by 











Hematology, Milan, Italy, 1971, p 181 
Abstract 
9. Curnutte JT, Karnovsky ML, Babior BM: Manganese-dependent NADPH
oxidation by a particulate preparation from guinea pig granulocytes: An alternative
interpretation. Clin Res 23:371A, 1975
Letter to Editor 
10. Seeler RA: Sickle cell anemia monthly variations. Blood 47: 879, 1976
PROOFREADING 
Contributors are provided with electronic galley proofs and are expected promptly to 
proofread them for typesetting errors and to answer all queries. Important changes in 
data are allowed, but authors will be charged for excessive alterations in proof. 
REPRINTS 
Reprints of articles can be furnished to contributors when ordered in advance of 
publication. An order form is sent in advance of proofs. Individuals wishing to obtain 
reprints of an article that appears in the Journal can do so by contacting the author at 
the address given in the Journal. Electronic copies may be purchased from the 
Publisher. 
CARDIAC CALENDAR
Announcements of meetings, conferences, and the like that are of interest to the 
readership of the Journal should be sent to the Section Editor for Cardiac Calendar, 
Dr. George Silvay (george.silvay@mountsinai.org), at least 3 months before the 
intended appearance of the notice. These announcements will be published only 
online. 
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